Business Description
Relief Therapeutics Holding SA
NAICS : 325412
ISIN : CH1251125998
Total Employee Number:
31Description
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.58 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.53 | |||||
Beneish M-Score | -2.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.9 | |||||
3-Year EBITDA Growth Rate | 28.6 | |||||
3-Year EPS without NRI Growth Rate | 48.6 | |||||
3-Year FCF Growth Rate | 64.5 | |||||
3-Year Book Growth Rate | -45.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.99 | |||||
9-Day RSI | 63.26 | |||||
14-Day RSI | 57.71 | |||||
3-1 Month Momentum % | 2.6 | |||||
6-1 Month Momentum % | 30.46 | |||||
12-1 Month Momentum % | -25.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.05 | |||||
Quick Ratio | 3.8 | |||||
Cash Ratio | 3.33 | |||||
Days Inventory | 176.54 | |||||
Days Sales Outstanding | 89.37 | |||||
Days Payable | 267.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | 1.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.24 | |||||
Operating Margin % | -211.69 | |||||
Net Margin % | -420.33 | |||||
EBITDA Margin % | -441.24 | |||||
FCF Margin % | -89 | |||||
OCF Margin % | -86.58 | |||||
ROE % | -43.12 | |||||
ROA % | -29.7 | |||||
ROIC % | -17.53 | |||||
3-Year ROIIC % | -15.39 | |||||
ROC (Joel Greenblatt) % | -822.45 | |||||
ROCE % | -37.37 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.88 | |||||
PS Ratio | 9.29 | |||||
PB Ratio | 1.16 | |||||
Price-to-Tangible-Book | 18.75 | |||||
EV-to-EBIT | -1.38 | |||||
EV-to-EBITDA | -1.52 | |||||
EV-to-Forward-EBITDA | -1.09 | |||||
EV-to-Revenue | 6.7 | |||||
EV-to-Forward-Revenue | 0.43 | |||||
EV-to-FCF | -7.53 | |||||
Price-to-GF-Value | 0.48 | |||||
Earnings Yield (Greenblatt) % | -72.46 | |||||
FCF Yield % | -9.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relief Therapeutics Holding SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 4.054 | ||
| EPS (TTM) (CHF) | -1.359 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.07 | ||
| Volatility % | 51.33 | ||
| 14-Day RSI | 57.71 | ||
| 14-Day ATR (CHF) | 0.153179 | ||
| 20-Day SMA (CHF) | 2.768 | ||
| 12-1 Month Momentum % | -25.75 | ||
| 52-Week Range (CHF) | 1.65 - 4.8 | ||
| Shares Outstanding (Mil) | 12.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relief Therapeutics Holding SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relief Therapeutics Holding SA Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-14 | In 49 days | ||
| General meeting for 2025 | 2026-06-12 10:00 | 2.86 (+2.14%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-10 07:00 | 2.86 (+2.14%) | ||
| Annual report for 2025 | 2026-04-10 | 2.86 (+2.14%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 3.12 (+20.23%) | ||
| General meeting for 2024 | 2025-06-12 10:00 | 2.18 (-3.11%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-10 07:00 | 2.19 (+9.23%) | ||
| Annual report for 2024 | 2025-04-10 | 2.19 (+9.23%) | ||
| Second quarter earnings results for 2024 | 2024-08-30 | 1.08 (+1.89%) | ||
| General meeting for 2023 | 2024-06-27 11:00 | 1.18 (+0.00%) |
Show
Entries
Relief Therapeutics Holding SA Frequently Asked Questions
What is Relief Therapeutics Holding SA(XSWX:RLF)'s stock price today?
The current price of XSWX:RLF is CHF3.00. The 52 week high of XSWX:RLF is CHF4.80 and 52 week low is CHF1.65.
When is next earnings date of Relief Therapeutics Holding SA(XSWX:RLF)?
The next earnings date of Relief Therapeutics Holding SA(XSWX:RLF) is 2026-08-14 Est..
Does Relief Therapeutics Holding SA(XSWX:RLF) pay dividends? If so, how much?
Relief Therapeutics Holding SA(XSWX:RLF) does not pay dividend.
Press Release
Articles on Relief Therapeutics Holding SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers